Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

Tanios Bekaii-Saab, MD
Published: Friday, Jun 30, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

In a study in pancreatic adenocarcinoma, the response rate of the combination of napabucasin with gemcitabine and nab-paclitaxel was close to 55%. This is promising, says Bekaii-Saab, as there is little response rate regularly seen in this disease.

More interestingly, the responses tended to be durable in most patients, with some approaching their second year of therapy.

<<< View more from the 2017 World Congress on GI Cancer


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

In a study in pancreatic adenocarcinoma, the response rate of the combination of napabucasin with gemcitabine and nab-paclitaxel was close to 55%. This is promising, says Bekaii-Saab, as there is little response rate regularly seen in this disease.

More interestingly, the responses tended to be durable in most patients, with some approaching their second year of therapy.

<<< View more from the 2017 World Congress on GI Cancer



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x